BIOAGE LABS INC (BIOA)

What BIOAGE LABS INC does

BioAge Labs is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform uses differentiated human datasets to identify promising drug targets based on molecular changes that drive aging. Its lead program, BGE-102, is a brain-penetrant, orally available NLRP3 inhibitor being evaluated for metabolic and cardiovascular indications, with additional APJ receptor programs in preclinical and early clinical development.

Fundamentals

• Price$24.89 as of 2026-07-09 close
• Market cap$1.1B as of 2026-07-10
• 1-year return+437.6% as of 2026-07-09 close
• Net margin-871.8% as of 2026-07-10
• ROE-29.4% as of 2026-07-10
• Debt / equity0.00 as of 2026-07-10
• Revenue growth (YoY)+91.0% as of 2026-07-10
• Beta1.97 as of 2026-07-10

Ask why BIOA looks like this →

Key risks (from latest filing)

["Clinical development risk: BGE-102 is in early-stage clinical trials with uncertain efficacy, safety, and regulatory path; unexpected adverse events or lack of efficacy could halt development or delay commercialization.","Regulatory and approval risk: Dependent on FDA designations and approvals; shifting FDA priorities, geopolitical factors, and regulatory changes could impact timing and success of clinical programs.","Cash burn and funding risk: Unprofitable with significant operating expenses; continued ability to fund clinical trials and operations dependent on capital availability and ability to raise additional funding."]

See BIOA's biggest risks from its latest 10-Q →

Competitors & peers

• Eli Lilly (LLY)
• Novo Nordisk (NVO)
• Viking Therapeutics
• Structure Therapeutics
• Rgenix

Not quite? Describe exactly what you want →